BMS, Pfizer report data for extended Eliquis treatment
Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) said twice-daily 2.5 and 5 mg Eliquis apixaban for one year as extended treatment for venous thromboembolism (VTE) each met the composite primary endpoint in the Phase III AMPLIFY-EXT trial. The endpoint was the incidence of symptomatic recurrent VTE or all-cause death vs. placebo. Both doses also met the composite secondary endpoint of reducing the incidence of recurrent VTE or VTE-related death vs. placebo.
The double-blind, international trial enrolled 2,486 patients with VTE who completed 6-12 months of prior anticoagulation therapy. Data were published in the New England Journal of Medicine and were presented at the American Society of Hematology meeting in Atlanta. ...